MEDICAL-MANAGEMENT SHOULD BE ROUTINELY USED AS PRIMARY THERAPY FOR ECTOPIC PREGNANCY

被引：24

作者：

STOVALL, TG

机构：

[1] Section on Gynecology, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, NC 27157-1066, Medical Center Blvd.

来源：

CLINICAL OBSTETRICS AND GYNECOLOGY | 1995年 / 38卷 / 02期

关键词：

D O I：

10.1097/00003081-199506000-00018

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

It does not appear that methotrexate can or should be used to totally replace laparoscopic salpingostomy. However, given its success rate in selected patients, its cost-effectiveness, and its low incidence of side effects, methotrexate therapy certainly can be used as an alternative therapy. The next step in developing this treatment option will be to conduct a randomized clinical trial comparing laparoscopic salpingostomy with intramuscular methotrexate. This type of study will answer questions regarding the patient's health related quality of life and economic impact of the two treatment modalities. For now, it seems prudent to offer methotrexate to those patients with an unruptured ectopic gestational mass 3.5 cm or less in greatest dimension.

引用

页码：346 / 352

页数：7

共 29 条

[1]

BERGER GS, 1994, J REPROD MED, V39, P569

[2]

BERKOWITZ RS, 1980, CANCER, V45, P423, DOI 10.1002/1097-0142(19800201)45:3<423::AID-CNCR2820450303>3.0.CO

[3]

2-G

[4]

BROWN DL, 1991, OBSTET GYNECOL, V164, P1420

[5]

BRUMSTED J, 1988, OBSTET GYNECOL, V71, P889

[6]

CREININ MD, 1993, FERTIL STERIL, V60, P963

[7]

FAYEZ JA, 1993, OBSTET GYNECOL, V81, P598

[8]

GOLDMAN ID, 1974, MOL PHARMACOL, V10, P257

[9]

GOLDMAN ID, 1974, MOL PHARMACOL, V10, P275

[10] REPRODUCTIVE-PERFORMANCE AFTER MOLAR PREGNANCY AND GESTATIONAL TROPHOBLASTIC TUMORS [J].

GOLDSTEIN, DP ;

BERKOWITZ, RS ;

BERNSTEIN, MR .

CLINICAL OBSTETRICS AND GYNECOLOGY, 1984, 27 (01) :221-227

← 1 2 3 →